(Q42873883)

9 November 2017

0 references

The next step for taribavirin (English)

1 reference

9 November 2017

Paul Y Kwo

1

1 reference

9 November 2017

Rakesh Vinayek

series ordinal

2

1 reference

9 November 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

9 November 2017

1 reference

9 November 2017

volume

52

1 reference

9 November 2017

issue

4

1 reference

9 November 2017

page(s)

1185-1188

1 reference

Conversion of viramidine to ribavirin in vivo by adenosine deaminase and its inhibition by 2'-deoxycoformycin.

9 November 2017

cites work

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

7 January 2021

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

1 reference

7 January 2021

Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy

1 reference

7 January 2021

Peginterferon and ribavirin for chronic hepatitis C.

1 reference

7 January 2021

Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus

1 reference

7 January 2021

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

1 reference

7 January 2021

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

7 January 2021

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

7 January 2021

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

1 reference

7 January 2021

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

7 January 2021

Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study

1 reference

7 January 2021

Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients.

1 reference

7 January 2021

A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.

1 reference

7 January 2021

Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

1 reference

7 January 2021

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

1 reference

7 January 2021

Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges

1 reference

7 January 2021

Treatment of hepatitis C: don't put all your eggs in one basket!

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.23957

1 reference

9 November 2017

1 reference